Is anti-TNF-alpha loss of response associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn 's disease?
Anti-TNF-α loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with CD.
The immunomodulatory molecule lenalidomide augments the response to BCG in an in vivo mouse model. This provides the rationale for studying the combination in patients with high grade NMIBC.